Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod.

< BACK TO ARCHIVE


2021 Jul 31


Arthritis Res Ther


http://www.ncbi.nlm.nih.gov/pubmed/34330322?dopt=Abstract


23


1

An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod.

Authors

An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod.
Hesselstrand R, Distler JHW, Riemekasten G, Wuttge DM, Törngren M, Nyhlén HC, Andersson F, Eriksson H, Sparre B, Tuvesson H, Distler O
Arthritis Res Ther. 2021 Jul 31; 23(1):204.
PMID: 34330322.

Abstract

To evaluate the changes in disease-related biomarkers and safety of paquinimod, an oral immunomodulatory compound, in patients with systemic sclerosis (SSc).
Read This Paper